CervoMed, a Boston-based biotechnology company with 8 employees, focuses on developing neflamapimod for neurodegenerative diseases and is conducting the RewinD-LB Phase 2b trial for dementia with Lewy bodies. The drug aims to modify disease processes and improve synaptic dysfunction.
CervoMed (CRVO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CervoMed's actual EPS was -$0.55, missing the estimate of -$0.42 per share, resulting in a -30.70% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
